AAPL 171.78 1.4649% MSFT 395.59 0.1646% GOOG 167.02 0.8758% GOOGL 165.1801 0.8056% AMZN 181.65 1.4804% NVDA 842.0 1.3957% META 436.29 -0.6603% TSLA 178.4049 -0.8807% TSM 134.165 -0.5743% LLY 765.395 -1.4619% V 267.43 0.0411% AVGO 1235.365 -0.603% JPM 190.79 -0.5577% UNH 490.05 1.227% NVO 125.83 -2.6159% WMT 59.675 1.4019% LVMUY 164.165 0.0884% XOM 116.75 0.6205% LVMHF 819.3109 -0.3671% MA 439.88 -0.4954%
Last update at 2024-05-02T14:53:00Z
Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
Income before tax | 4630.00M | 1928.00M | -5034.00000M | 1144.00M | 610.00M |
Minority interest | 162.00M | -173.00000M | 199.00M | 220.00M | 221.00M |
Net income | 3560.00M | 1114.00M | -4339.00000M | 900.00M | 34.00M |
Selling general administrative | 15552.00M | 21074.00M | 17698.00M | 18336.00M | 8403.00M |
Selling and marketing expenses | -7776.00000M | -10537.00000M | -8849.00000M | -9168.00000M | 8403.00M |
Gross profit | 12358.00M | 13130.00M | 12148.00M | 12023.00M | 11754.00M |
Reconciled depreciation | 608.00M | 760.00M | 887.00M | 922.00M | 949.00M |
Ebit | 4381.00M | 2852.00M | 3522.00M | 1663.00M | 3268.00M |
Ebitda | 5687.00M | 3612.00M | 4409.00M | 2585.00M | 4217.00M |
Depreciation and amortization | 1306.00M | 760.00M | 887.00M | 922.00M | 949.00M |
Non operating income net other | 497.00M | 68.00M | 223.00M | 12.00M | -12.00000M |
Operating income | 4381.00M | 2852.00M | 3522.00M | 1663.00M | 886.00M |
Other operating expenses | 272129.00M | 261373.00M | 234929.00M | 228292.00M | 211039.00M |
Interest expense | 248.00M | 178.00M | 217.00M | 249.00M | 264.00M |
Tax provision | 905.00M | 636.00M | -695.00000M | 18.00M | 356.00M |
Interest income | 248.00M | 10.00M | 217.00M | 49.00M | 39.00M |
Net interest income | -248.00000M | -178.00000M | -217.00000M | -200.00000M | -225.00000M |
Extraordinary items | -3.00000M | -5.00000M | -1.00000M | -6.00000M | 87.00M |
Non recurring | -8.00000M | 274.00M | 8339.00M | 270.00M | 2394.00M |
Other items | - | - | - | - | - |
Income tax expense | 905.00M | 636.00M | -695.00000M | 18.00M | 356.00M |
Total revenue | 276711.00M | 263966.00M | 238228.00M | 231051.00M | 214319.00M |
Total operating expenses | 7776.00M | 10537.00M | 8849.00M | 9264.00M | 8474.00M |
Cost of revenue | 264353.00M | 250836.00M | 226080.00M | 219028.00M | 202565.00M |
Total other income expense net | 249.00M | -924.00000M | -8556.00000M | -519.00000M | -2406.00000M |
Discontinued operations | -3.00000M | -5.00000M | -1.00000M | -6.00000M | 1.00M |
Net income from continuing ops | 3725.00M | 1292.00M | -4339.00000M | 1126.00M | 254.00M |
Net income applicable to common shares | 3560.00M | 1114.00M | -4539.00000M | 900.00M | 34.00M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
Total assets | 62320.00M | 63298.00M | 65015.00M | 61247.00M | 59672.00M |
Intangible assets | 2277.00M | 2059.00M | 2878.00M | 3156.00M | 3689.00M |
Earning assets | - | - | - | - | - |
Other current assets | 496.00M | 5414.00M | 665.00M | 617.00M | 529.00M |
Total liab | 63810.00M | 65090.00M | 63569.00M | 54536.00M | 49992.00M |
Total stockholder equity | -1857.00000M | -2272.00000M | -21.00000M | 5092.00M | 8094.00M |
Deferred long term liab | 1387.00M | 1418.00M | 1411.00M | 2255.00M | 2998.00M |
Other current liab | 4200.00M | 9284.00M | 9.00M | 683.00M | 3443.00M |
Common stock | 3.00M | 2.00M | 2.00M | 2.00M | 3.00M |
Capital stock | 3.00M | 2.00M | 2.00M | 2.00M | 3.00M |
Retained earnings | 12295.00M | 9030.00M | 8202.00M | 13022.00M | 12409.00M |
Other liab | 9808.00M | 10142.00M | 11193.00M | 3917.00M | 5068.00M |
Good will | 9947.00M | 9451.00M | 9493.00M | 9360.00M | 9358.00M |
Other assets | 1755.00M | 1251.00M | 2581.00M | 1858.00M | 1705.00M |
Cash | 4678.00M | 3532.00M | 6278.00M | 4015.00M | 2981.00M |
Cash and equivalents | 4678.00M | 3532.00M | 6278.00M | 4015.00M | 2981.00M |
Total current liabilities | 47957.00M | 48466.00M | 44103.00M | 42624.00M | 37626.00M |
Current deferred revenue | - | - | 3987.00M | 3340.00M | - |
Net debt | 2617.00M | 4010.00M | 3127.00M | 5386.00M | 4614.00M |
Short term debt | 1267.00M | 1096.00M | 1132.00M | 1406.00M | 330.00M |
Short long term debt | 968.00M | 799.00M | 742.00M | 1052.00M | 330.00M |
Short long term debt total | 7295.00M | 7542.00M | 9405.00M | 9401.00M | 7595.00M |
Other stockholder equity | -13250.00000M | -9770.00000M | -6745.00000M | -6229.00000M | -2469.00000M |
Property plant equipment | 2177.00M | 2092.00M | 2581.00M | 2365.00M | 2548.00M |
Total current assets | 44292.00M | 46231.00M | 45382.00M | 42222.00M | 38465.00M |
Long term investments | - | - | - | 0.00000M | 3513.00M |
Net tangible assets | -12679.00000M | -12416.00000M | -9254.00000M | -4362.00000M | -3560.00000M |
Short term investments | - | - | - | - | - |
Net receivables | 19410.00M | 18583.00M | 19181.00M | 19950.00M | 18246.00M |
Long term debt | 4626.00M | 5080.00M | 6406.00M | 6335.00M | 7265.00M |
Inventory | 19691.00M | 18702.00M | 19246.00M | 16734.00M | 16709.00M |
Accounts payable | 42490.00M | 38086.00M | 38975.00M | 37195.00M | 33853.00M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | 367.00M | 480.00M | 196.00M | 217.00M | 193.00M |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -905.00000M | -1534.00000M | -1480.00000M | -1703.00000M | -1849.00000M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | 3.00M | 2.00M | 2.00M | 2.00M | 3.00M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | 12295.00M | 9030.00M | 8202.00M | 13022.00M | 12409.00M |
Treasury stock | - | -17045.00000M | -13670.00000M | -12892.00000M | -8902.00000M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 1992.00M | 1917.00M | 2581.00M | 2258.00M | 2099.00M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 18028.00M | 17067.00M | 19633.00M | 19025.00M | 21207.00M |
Capital lease obligations | 1701.00M | 1663.00M | 2257.00M | 2014.00M | - |
Long term debt total | 4626.00M | 5080.00M | 6406.00M | 6335.00M | 7265.00M |
Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
Investments | -542.00000M | -89.00000M | 400.00M | 37.00M | -1381.00000M |
Change to liabilities | 4151.00M | 3045.00M | 1101.00M | 3944.00M | 1881.00M |
Total cashflows from investing activities | -542.00000M | -89.00000M | -415.00000M | -579.00000M | -1381.00000M |
Net borrowings | -277.00000M | -1334.00000M | -540.00000M | -298.00000M | -16.00000M |
Total cash from financing activities | -4368.00000M | -6321.00000M | -1693.00000M | -2734.00000M | -2227.00000M |
Change to operating activities | -1370.00000M | 49.00M | 8216.00M | -377.00000M | -377.00000M |
Net income | 3722.00M | 1287.00M | -4340.00000M | 1120.00M | 255.00M |
Change in cash | 743.00M | -2461.00000M | 2373.00M | 1042.00M | 309.00M |
Begin period cash flow | 3935.00M | 6396.00M | 4023.00M | 2981.00M | 2672.00M |
End period cash flow | 4678.00M | 3935.00M | 6396.00M | 4023.00M | 2981.00M |
Total cash from operating activities | 5159.00M | 4434.00M | 4542.00M | 4374.00M | 4036.00M |
Issuance of capital stock | 163.00M | 220.00M | 92.00M | 113.00M | 75.00M |
Depreciation | 608.00M | 760.00M | 887.00M | 922.00M | 949.00M |
Other cashflows from investing activities | -152.00000M | 299.00M | -364.00000M | -254.00000M | -955.00000M |
Dividends paid | -292.00000M | -277.00000M | -276.00000M | -294.00000M | 292.00M |
Change to inventory | -1259.00000M | -1169.00000M | -2276.00000M | -376.00000M | -368.00000M |
Change to account receivables | -1082.00000M | -1843.00000M | 1145.00M | -2494.00000M | -967.00000M |
Sale purchase of stock | -3638.00000M | -3516.00000M | -770.00000M | -1954.00000M | -1639.00000M |
Other cashflows from financing activities | 9123.00M | 10092.00M | 6624.00M | 21136.00M | 38009.00M |
Change to netincome | 140.00M | 2064.00M | -525.00000M | 193.00M | 2304.00M |
Capital expenditures | 558.00M | 535.00M | 641.00M | 506.00M | 557.00M |
Change receivables | -1082.00000M | -1843.00000M | 1145.00M | -2494.00000M | -967.00000M |
Cash flows other operating | -1121.00000M | 290.00M | 8550.00M | 1065.00M | 68.00M |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | 249.00M | -1976.00000M | 2434.00M | 1061.00M | 428.00M |
Change in working capital | 384.00M | 82.00M | 8186.00M | 689.00M | 546.00M |
Stock based compensation | - | - | 233.00M | 1223.00M | 2273.00M |
Other non cash items | 465.00M | 2271.00M | 484.00M | 762.00M | -176.00000M |
Free cash flow | 4601.00M | 3899.00M | 3901.00M | 3868.00M | 3479.00M |
Sector: Healthcare Industry: Medical Distribution
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
MCK McKesson Corporation |
1.93 0.36% | 533.02 | 17.95 | 14.53 | 0.20 | 5.04 | 0.22 | 12.17 |
COR Cencora Inc. |
-2.53 1.10% | 226.67 | 23.39 | - | - | - | ||
CAH Cardinal Health Inc |
4.10 4.01% | 106.27 | 166.11 | 14.71 | 0.12 | 16.07 | 0.12 | 19.78 |
HSIC Henry Schein Inc |
-0.26 0.38% | 68.52 | 21.82 | 14.33 | 0.76 | 2.63 | 0.92 | 12.98 |
SHPMF Shanghai Pharmaceuticals Holding Co. Ltd |
- -% | 1.21 | 7.71 | 5.45 | 0.03 | 0.57 | 0.03 | 0.88 |
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
6555 State Highway 161, Irving, TX, United States, 75039
Name | Title | Year Born |
---|---|---|
Mr. Brian S. Tyler Ph.D. | CEO & Director | 1967 |
Mr. Britt J. Vitalone | Exec. VP & CFO | 1969 |
Ms. Nancy Avila | Exec. VP, Chief Information Officer & CTO | 1967 |
Ms. Lori A. Schechter J.D. | Exec. VP, Chief Legal Officer & Gen. Counsel | 1962 |
Mr. Napoleon B. Rutledge Jr. | Sr. VP, Controller & Chief Accounting Officer | 1972 |
Ms. Holly Weiss | Sr. VP of Investor Relations | NA |
Mr. Pete Slone | Sr. VP of Corp. Public Affairs | NA |
Ms. LeAnn B. Smith | Exec. VP & Chief HR Officer | NA |
Mr. Kirk Kaminsky | Pres of The US Pharmaceutical & Specialty Solutions Bus. | NA |
Paul A. Smith | Sr. VP of Taxes | NA |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).